Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate
Maternal Killer Cell Immunoglobulin-like Receptors (KIR) and Fetal (Human Leukocyte Antigen) HLA-C Compatibility in ART-oocyte Donor Influences Live Birth Rate a Prospective Controlled Cohort Study
1 other identifier
observational
200
1 country
1
Brief Summary
Has the maternal KIR haplotype an impact in pregnancy, miscarriage and live birth rates per embryo transfer in donor oocytes -ART by paternal and oocyte donor HLA-C?
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 11, 2016
CompletedFirst Posted
Study publicly available on registry
March 24, 2016
CompletedStudy Start
First participant enrolled
January 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2022
CompletedAugust 11, 2022
August 1, 2022
3 months
March 11, 2016
August 9, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Compatibility maternal fetal KIR HLA-C
KIR haplotype regions will be defined by the presence of the following KIR genes: Cen-A/2DL3: Tel-A/3DL1 and 2DS4; Cen-B/2DL2 and 2DS2; Tel-B/2DS1 and 3DS1. The HLA-C ligands for KIRs will be divided into 2 groups: HLA-C1 and HLA\_C2
2 years
Study Arms (1)
Receiver patients in donor oocyte -ART
Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor
Interventions
We will take blood samples for KIR HLA-C determinations.
Eligibility Criteria
Patients undergoing an assisted reproductive treatment
You may qualify if:
- BMI between 19 - 27 kg/m2
- Blastocyst embryo transfer previous.
- Normal karyotype, thrombophylic and immunological results.
- Normal clinical history, viral serology, hormonal analysis (TSH, T4, prolactin, estrogen, progesterone), spermiogram, sperm FISH and pelvic ultrasound results.
You may not qualify if:
- Pregnancy women.
- Psychiatric disorders.
- Uterus alterations.
- Polycystic ovary syndrome
- Genetic and autoimmune diseases.
- Infectious diseases.
- Corticoid and immunosuppressant treatments previous.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- IVI Madridlead
Study Sites (1)
Instituto Valenciano de Infertilidad
Madrid, 28035, Spain
Biospecimen
Genomic DNA will be obtained and will be studied in Professor Moffet laboratory in Cambridge (department of Pathologí, University of Cambridge) KIR typing including copi number and HLA-C loci will be performed as previously described (Hiby 2010, Jiang 2012). KIR haplotype regions will be defined by the presence of the following KIR genes: Cen-A/2DL3; Tel-A/3DL1 and 2DS4; Cen-B/2DL2 and 2DS2; Tel-B/2DS1 and 3DS1. The HLA-C ligands for KIRs will be divided into 2 groups: HLA-C1 and HLA-C2.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Juan Antonio Garcia Velasco, PhD
IVI Madrid
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- PhD
Study Record Dates
First Submitted
March 11, 2016
First Posted
March 24, 2016
Study Start
January 1, 2022
Primary Completion
April 1, 2022
Study Completion
August 1, 2022
Last Updated
August 11, 2022
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share